Delcath Systems (NASDAQ:DCTH) Stock: Insider Bridget Martell Sells 22,500 Shares

Delcath Systems, Inc. (NASDAQ:DCTH – Get Free Report) Director Bridget Martell sold 22,500 shares of the business’s stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $21.71, for a total value of $488,475.00. Following the transaction, the director directly owned 22,500 shares of the company’s stock, valued at approximately $488,475. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Delcath Systems Price Performance

Shares of DCTH stock traded down $0.83 during trading hours on Friday, reaching $20.55. 675,186 shares of the stock were exchanged, compared to its average volume of 734,330. The business’s fifty day moving average is $15.88 and its two-hundred day moving average is $12.70. Delcath Systems, Inc. has a 12-month low of $8.12 and a 12-month high of $22.51. The firm has a market capitalization of $714.93 million, a P/E ratio of 128.44 and a beta of 0.62.

Delcath Systems (NASDAQ:DCTH – Get Free Report) last issued its earnings results on Monday, November 9th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.26. Delcath Systems had a net margin of 6.05% and a return on equity of 5.56%. The firm had revenue of $35.10 million for the quarter, compared to analysts’ expectations of $25.99 million. As a group, equities research analysts predict that Delcath Systems, Inc. will post 0.13 earnings per share for the current fiscal year.

Delcath Systems News Summary

These are some of the DCTH news items that stood out recently:

  • Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $36 price target, raising its FY2026 EPS forecast from a loss of $0.17 to earnings of $0.13 and its FY2027 estimate from $0.12 to $0.33. It also expects a narrower Q4 2026 loss. MarketBeat analyst estimates
  • Negative Sentiment: Director Bridget A. Martell sold 22,500 shares for about $488,475, cutting her stake by 50%. Insider sales can raise concern, though the filing does not state the reason for the transaction. SEC Form 4
  • Negative Sentiment: A separate report said an analyst reduced its Q2 EPS forecast; details of the revised estimate were not provided. Analyst forecast report

Hedge Funds Weigh In On Delcath Systems

Several large investors have recently bought and sold shares of the stock. Integrated Wealth Concepts LLC acquired a new stake in shares of Delcath Systems during the second quarter worth about $48,000. IFP Advisors Inc purchased a new position in Delcath Systems during the 2nd quarter worth approximately $52,000. Royal Bank of Canada grew its stake in Delcath Systems by 14.8% during the 1st quarter. Royal Bank of Canada now owns 18,383 shares of the company’s stock worth $170,000 after buying an additional 2,364 shares during the last quarter. Entropy Technologies LP acquired a new position in Delcath Systems during the third quarter worth approximately $328,000. Finally, Kopp Family Office LLC purchased a new stake in Delcath Systems in the third quarter valued at approximately $450,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on DCTH. Weiss Ratings upgraded shares of Delcath Systems from a “hold (c-)” rating to a “hold (c+)” rating in a research note on Thursday. BTIG Research raised their price target on Delcath Systems from $21.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, November 9th. HC Wainwright upped their price objective on Delcath Systems from $32.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, November 10th. Wall Street Zen upgraded Delcath Systems from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Zacks Research raised Delcath Systems from a “hold” rating to a “strong-buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $29.33.

Check Out Our Latest Analysis on Delcath Systems

About Delcath Systems

(Get Free Report)

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.

Recommended Stories

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.